Abstract
Uveitis is a sight threatening intraocular inflammation accounting for approximately 10% of blindness worldwide. On the basis of aetiology, disease can be classified as infectious or non-infectious; and by anatomical localization of inflammation as anterior, posterior and panuveitis. Non-infectious uveitis is believed to be autoimmune in nature with Th1 and Th17 cells being identified as the prominent effector cell types. Numerous animal models of autoimmune uveitis were developed contributing to our understanding of this inflammatory condition. The classical peptide-induced experimental autoimmune uveoretinitis (EAU) model resembles human posterior uveitis due to the recurrent/relapsing nature of the disease; while the intraocular inflammation triggered by administration of bacterial lipopolisaccharide (endotoxin-induced uveitis, EIU) mimics closely anterior uveitis. The clinical need for novel, more targeted forms of anti-inflammatory therapy has emerged as currently available therapeutic strategies are associated with a number of adverse effects and intolerance in patients. This review summarises knowledge about existing mouse models of uveitis, discusses mechanisms driving intraocular inflammation and describes possible customised translational treatment strategies that can be potentially used in the clinic to prevent blindness in patients.
Keywords: Uveitis, autoimmunity, inflammation, uveitogenic antigens, animal models, Th1, Th17.
Current Pharmaceutical Design
Title:Mouse Models of Autoimmune Uveitis
Volume: 21 Issue: 18
Author(s): Izabela P. Klaska and John V. Forrester
Affiliation:
Keywords: Uveitis, autoimmunity, inflammation, uveitogenic antigens, animal models, Th1, Th17.
Abstract: Uveitis is a sight threatening intraocular inflammation accounting for approximately 10% of blindness worldwide. On the basis of aetiology, disease can be classified as infectious or non-infectious; and by anatomical localization of inflammation as anterior, posterior and panuveitis. Non-infectious uveitis is believed to be autoimmune in nature with Th1 and Th17 cells being identified as the prominent effector cell types. Numerous animal models of autoimmune uveitis were developed contributing to our understanding of this inflammatory condition. The classical peptide-induced experimental autoimmune uveoretinitis (EAU) model resembles human posterior uveitis due to the recurrent/relapsing nature of the disease; while the intraocular inflammation triggered by administration of bacterial lipopolisaccharide (endotoxin-induced uveitis, EIU) mimics closely anterior uveitis. The clinical need for novel, more targeted forms of anti-inflammatory therapy has emerged as currently available therapeutic strategies are associated with a number of adverse effects and intolerance in patients. This review summarises knowledge about existing mouse models of uveitis, discusses mechanisms driving intraocular inflammation and describes possible customised translational treatment strategies that can be potentially used in the clinic to prevent blindness in patients.
Export Options
About this article
Cite this article as:
Klaska P. Izabela and Forrester V. John, Mouse Models of Autoimmune Uveitis, Current Pharmaceutical Design 2015; 21(18) . https://dx.doi.org/10.2174/1381612821666150316122928
DOI https://dx.doi.org/10.2174/1381612821666150316122928 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine Concurrence of Talaromycosis and Kaposi Sarcoma in an HIV-Infected Patient: A Case Report
Current HIV Research Predictors of Avascular Necrosis in a Cohort of Egyptian Systemic Lupus Erythematosus Patients: Retrospective Two Centers Study
Current Rheumatology Reviews Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews EDITORIAL (Thematic Issue: Serpins as Therapeutics – A Potential Biologic Source for Unique Protein-based Therapeutics)
Cardiovascular & Hematological Disorders-Drug Targets Small-Molecule Chemokine Receptor Antagonists: Potential Targets for Inflammatory and Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets VDAC-Targeted Drugs Affecting Cytoprotection and Mitochondrial Physiology in Cerebrovascular and Cardiovascular Diseases
Current Medicinal Chemistry Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Vaccination Against High Blood Pressure
Current Pharmaceutical Design Role of Platelets in Angiogenesis in Health and Disease
Current Angiogenesis (Discontinued) Antibody - Fc Receptor Interactions in Antimicrobial Functions
Current Immunology Reviews (Discontinued) Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews